Imexpharm Corp
VN:IMP
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38 750
55 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| VN |
I
|
Imexpharm Corp
VN:IMP
|
8.3T VND |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
521.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
274B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
206.4B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.8B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD |
Loading...
|
Market Distribution
| Min | -67 046.2% |
| 30th Percentile | 1.4% |
| Median | 4% |
| 70th Percentile | 9.8% |
| Max | 1 155.9% |
Other Profitability Ratios
Imexpharm Corp
Glance View
Imexpharm Corp. engages in the manufacture, import, export and trade of pharmaceuticals, medicinal chemicals and botanical. The company is headquartered in Cao Lanh, Dong Thap and currently employs 1,356 full-time employees. The company went IPO on 2006-12-04. The firm manufactures, imports, exports and trades pharmaceutical products, antiseptics, traditional medicine, medical equipment and supplies, cosmetics, supplemental food and drinks. The company is also involved in the provision of packaging services and warehousing services for pharmaceutical storage purposes. In addition, the Company is involved in medicinal herb cultivation.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Imexpharm Corp is 13%, which is above its 3-year median of 12.6%.
Over the last 3 years, Imexpharm Corp’s Net Margin has decreased from 13.9% to 13%. During this period, it reached a low of 11.2% on Dec 31, 2022 and a high of 13.9% on Dec 31, 2023.